MA45031A - Anticorps et leurs procédés d'utilisation dans le traitement de maladies infectieuses - Google Patents

Anticorps et leurs procédés d'utilisation dans le traitement de maladies infectieuses

Info

Publication number
MA45031A
MA45031A MA045031A MA45031A MA45031A MA 45031 A MA45031 A MA 45031A MA 045031 A MA045031 A MA 045031A MA 45031 A MA45031 A MA 45031A MA 45031 A MA45031 A MA 45031A
Authority
MA
Morocco
Prior art keywords
antibodies
treatment
methods
infectious diseases
infectious
Prior art date
Application number
MA045031A
Other languages
English (en)
Inventor
Frank Beurskens
Jong Rob De
Annemarie Kuipers
Paul Parren
Suzan Rooijakkers
Janine Schuurman
Kristin Strumane
Kessel Kok Van
Strijp Jos Van
Original Assignee
Genmab Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genmab Bv filed Critical Genmab Bv
Publication of MA45031A publication Critical patent/MA45031A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MA045031A 2016-05-18 2017-05-17 Anticorps et leurs procédés d'utilisation dans le traitement de maladies infectieuses MA45031A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA201600305 2016-05-18

Publications (1)

Publication Number Publication Date
MA45031A true MA45031A (fr) 2019-03-27

Family

ID=58992805

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045031A MA45031A (fr) 2016-05-18 2017-05-17 Anticorps et leurs procédés d'utilisation dans le traitement de maladies infectieuses

Country Status (11)

Country Link
US (2) US20200123237A1 (fr)
EP (1) EP3458089A1 (fr)
JP (2) JP2019519509A (fr)
KR (2) KR20190005998A (fr)
CN (1) CN109475618A (fr)
AU (1) AU2017266288A1 (fr)
BR (1) BR112018073050A2 (fr)
CA (1) CA3024476A1 (fr)
EA (1) EA201892655A1 (fr)
MA (1) MA45031A (fr)
WO (1) WO2017198731A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220130724A (ko) * 2020-01-16 2022-09-27 젠맵 에이/에스 Cd38 항체의 제제 및 그의 용도

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
EP1176195B1 (fr) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
AU7950400A (en) 1999-10-19 2001-04-30 Kyowa Hakko Kogyo Co. Ltd. Process for producing polypeptide
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CN102311986B (zh) 2000-10-06 2015-08-19 协和发酵麒麟株式会社 产生抗体组合物的细胞
CA2424977C (fr) 2000-10-06 2008-03-18 Kyowa Hakko Kogyo Co., Ltd. Procede de purification d'un anticorps
WO2002072600A2 (fr) 2001-01-26 2002-09-19 Inhibitex, Inc. Anticorps monoclonaux contre la proteine clfa et procede d'utilisation dans le traitement et la prevention d'infections
US20030157108A1 (en) 2001-10-25 2003-08-21 Genentech, Inc. Glycoprotein compositions
CA2507711A1 (fr) * 2002-12-02 2004-06-17 Biosynexus Incorporated Acide teichoique a paroi en tant que cible pour therapies et vaccins anti-staphylococciques
CA2677771A1 (fr) 2007-03-01 2008-09-04 Symphogen A/S Procede de clonage d'anticorps apparentes
AU2009246510B2 (en) 2008-05-12 2014-02-13 Strox Biopharmaceuticals, Llc Staphylococcus aureus-specific antibody preparations
PL2560993T3 (pl) 2010-04-20 2024-11-04 Genmab A/S Heterodimeryczne białka zawierające region FC przeciwciała i sposoby ich wytwarzania
UA117901C2 (uk) * 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
CN102654260B (zh) 2011-09-29 2014-09-03 北京京东方光电科技有限公司 一种背光源和液晶显示器
US20140212409A1 (en) * 2012-08-13 2014-07-31 Kyowa Hakko Kirin Co., Ltd. METHOD FOR INCREASING DEPOSITION OF COMPLEMENT C3b ON BACTERIAL SURFACE AND PHAGOCYTOSIS BY PHAGOCYTE AND A THERAPEUTIC METHOD AND A THERAPEUTIC AGENT FOR BACTERIAL INFECTIONS
WO2014027698A1 (fr) 2012-08-13 2014-02-20 Kyowa Hakko Kirin Co., Ltd. Anticorps monoclonal anti-polysaccharide de capsule de staphylococcus aureus
KR20240123420A (ko) 2013-01-10 2024-08-13 젠맵 비. 브이 인간 IgG1 Fc 영역 변이체 및 그의 용도
CA2910029A1 (fr) 2013-05-31 2014-12-04 Genentech, Inc. Anticorps anti-acide teichoique de la paroi cellulaire et conjugues associes
US9803002B2 (en) * 2013-05-31 2017-10-31 Genentench, Inc. Anti-wall teichoic antibodies and conjugates
JP6506262B2 (ja) 2013-05-31 2019-04-24 ジェネンテック， インコーポレイテッド 抗細胞壁タイコ酸抗体及びコンジュゲート

Also Published As

Publication number Publication date
WO2017198731A1 (fr) 2017-11-23
KR20230021765A (ko) 2023-02-14
KR20190005998A (ko) 2019-01-16
EP3458089A1 (fr) 2019-03-27
BR112018073050A2 (pt) 2019-02-26
US20200123237A1 (en) 2020-04-23
CA3024476A1 (fr) 2017-11-23
AU2017266288A1 (en) 2019-01-03
EA201892655A1 (ru) 2019-04-30
JP2022105143A (ja) 2022-07-12
US20220332801A1 (en) 2022-10-20
JP2019519509A (ja) 2019-07-11
CN109475618A (zh) 2019-03-15

Similar Documents

Publication Publication Date Title
EP3645742A4 (fr) Anticorps anti-ror1 et leurs procédés de préparation et d'utilisation
FR24C1044I2 (fr) Anticorps anti-c5 et leurs procédés d'utilisation
MA52753A (fr) Anticorps anti-sirpa et leurs procédés d'utilisation
MA50948A (fr) Anticorps et procédés d'utilisation de ceux-ci
MA46529A (fr) Anticorps anti-lag-3 et leurs procédés d'utilisation
MA42446A (fr) Anticorps spécifiques de la protéine tau hyperphosphorylée et leurs procédés d'utilisation
EP3472200A4 (fr) Anticorps anti-myostatine et leurs procédés d'utilisation
EP3383412A4 (fr) Anticorps spécifiques de la protéine pd-1 glycosylée et leurs procédés d'utilisation
MA56165A (fr) Anticorps spécifiques de la protéine tau hyperphosphorylée et leurs procédés d'utilisation
MA49950A (fr) Anticorps anti-b7-h4 et leurs procédés d'utilisation
MA53355A (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
EP3386536A4 (fr) Composition de conjugués d'agonistes-constructions d'anticorps et leurs procédés d'utilisation
EP3491025A4 (fr) Anticorps fcrn et leurs procédés d'utilisation
MA42043A (fr) Anticorps anti-ox40 et procédés d'utilisation de ceux-ci
MA42971A (fr) Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
EP3436476A4 (fr) Anticorps anti-ryk et leurs procédés d'utilisation
MA47849A (fr) Anticorps anti-gitr et leurs procédés d'utilisation
MA43018A (fr) Anticorps anti-pd1 et procédés d'utilisation
EP3362479A4 (fr) Agents de type anticorps spécifiques de l'antigène cd19 humain et leurs utilisations
EP3472316A4 (fr) Anticorps anti-c5 et leurs procédés d'utilisation
EP3731867A4 (fr) Anticorps anti-lrp5/6 et leurs procédés d'utilisation
EP3394098A4 (fr) Anticorps anti-myostatine et procédés d'utilisation
EP3645049A4 (fr) Anticorps multispécifiques et procédés de préparation et d'utilisation associés
EP3512517A4 (fr) Utilisation de pridopidine pour le traitement de l'anxiété et de la dépression
EP3710589A4 (fr) Anticorps anti-c1s et procédés d'utilisation